石四药集团(02005)：头孢氨苄胶囊(0.25g及0.125g)取得国家药监局批准通过仿制药质量和疗效一致性评价
石四药集团(02005)发布公告，集团的头孢氨苄胶囊(0.25g及0.125g)已取得中国国家药品监督管理局批准通过仿制药质量和疗效一致性评价。头孢氨苄胶囊主要用于治疗敏感菌所致的急性扁桃体炎、咽峡炎、鼻窦炎、支气管炎、肺炎等呼吸道感染、中耳炎、尿路感染及皮肤软组织感染等。
此外，集团的甲磺酸多沙唑嗪已获国家药监局批准登记成为在上市制剂使用的原料药。甲磺酸多沙唑嗪是一种抗高血压药，主要用于原发性轻或中度高血压及伴有良性前列腺肥大的高血压患者。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.